$QNTA trading low volume compared to its 10-day average volume with less than 2.5 hours left in the day, but still holding steady around a penny. Looking forward to seeing updates from the company.
By the end of January, the Company expects to receive an export license for Escozine that is produced in the DR, after which the Company intends to begin exporting Escozine to Mexico for further distribution. In the meantime, the Company continues to work towards finalizing its DNA toxicology study on Escozine, in connection with the product’s PIND application. The Company is also working with FINRA on completing the application to change Quanta’s name and stock symbol, and expects to receive approval during Q1 2022.
News 
Market Data 
Discover 
